LiebermanS.A., OberoiA.L., GilkisonC.R., MaselB.E., and UrbanR.J. (2001). Prevalence of neuroendocrine dysfunction in patients recovering from traumatic brain injury. J. Clin. Endocrinol. Metab. 86, 2752–2756.
2.
KellyD.F., GonzaloI.T., CohanP., BermanN., SwerdloffR., and WangC. (2000). Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report. J. Neurosurg. 93, 743–752.
3.
SchneiderH.J., Kreitschmann-AndermahrI., GhigoE., StallaG.K., and AghaA. (2007). Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA, 298, 1429–1438.
4.
LauzierF., TurgeonA.F., BoutinA., ShemiltM., CôtéI., LachanceO., ArchambaultP.M., LamontagneF., MooreL., BernardF., GagnonC., and CookD. (2014). Clinical outcomes, predictors, and prevalence of anterior pituitary disorders following traumatic brain injury: a systematic review. Crit. Care Med. 42, 712–721.
5.
HighW.M.Jr., Briones-GalangM., ClarkJ.A., GilkisonC., MossbergK.A., ZgaljardicD.J., MaselB.E., and UrbanR.J. (2010). Effect of growth hormone replacement therapy on cognition after traumatic brain injury. J. Neurotrauma, 27, 1565–1575.
6.
MossbergK.A., DurhamW.J., ZgaljardicD.J., GilkisonC.R., DanesiC.P., Sheffield-MooreM., MaselB.E., and UrbanR.J. (2017). Functional changes after recombinant human growth hormone replacement in patients with chronic traumatic brain injury and abnormal growth hormone secretion. J. Neurotrauma, 34, 845–852.
